TGF Beta Receptor Dynamics
TGF Beta Receptor Dynamics
批准号:
8579997
负责人:
EDWARD B LEOF
金额:
$38.16万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-05-01 至 2019-04-30
关键词:
AddressBiochemicalBiologicalBiologyCarrier ProteinsCell membraneCessation of lifeChronicCicatrixClathrinComplexDataDefectDiseaseElementsEndosomesEpithelial CellsFibrosisGeneticGlioblastomaGrowthHealthHumanInstructionInterventionLocalesLungMalignant NeoplasmsMesenchymalModelingOrganPathway interactionsPhenotypePhysiologicalPlasmaPlatelet-Derived Growth FactorProteinsReceptor Protein-Tyrosine KinasesRecyclingRespiratory physiologyRoleSignal TransductionSorting - Cell MovementSpecificityThe SunTrans-ActivatorsTransforming Growth Factor betaTransforming Growth Factor beta ReceptorsWound Healingcell growthchemoradiationmigrationnexinnovel strategiespre-clinicalpreventprotein transportreceptorresponsetrafficking
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ProgramDirector/PrincipalInvestigator(Last,Rrst,Middle):Leof,Edward,B
PROJECT SUMMARY (See Instmctions):
A central paradox in transforming growth factor beta (TGF-p) biology is how the same growth ^ctor can
induce such divergent responses as growth stimulation (i.e., mesenchymal cells) and growth inhibition (i.e.,
epithelial cells)? Considering the pivotal role TGF-^ has in a number of nomial and pathological conditions,
addressing that issue is fundamental if we hope to develop specific intervention strategies. To that end, we
have been investigating the general hypothesis that the cellular response to TGF-¿ is dependent upon
an integrated action ofthe trafficldng and signaling machinery. In support of that proposal, we have
detemiined that (i) in polarized epithelial cells TGF-p receptors traffic to the basolateral domain, adjacent to
the junctional complex; (ii) the mammalian retromer complex specifically maintains type II TGF-p receptor
polarity by controlling recycling endosome to plasma membrane delivery by way of clathrin, EEA1 and
Rab11 positive compartments; (iii) sorting nexin 9 (SNX9), a known trafficking protein, has a new role in
TGF-p signaling downstream of its canonical plasma membriane action; (iv) an unique mechanism has been
defined by which specificity in TGF-p signaling can be controlled and subsequently exploited to treat
diseases dependent upon Smad3; (v) profibrotic TGF-p responses require the cooperative action of PDGF
and ErbB receptor tyrosine kinases; and, most importantly, (vi) utilizing a treatment model of lung fibrosis,
provided preclinical data documenting that physiologic parameters of lung function can be stabilized by
targeting multiple TGF-p regulated pathways. We propose to extend these findings using a variety of
biochemical, biological, and genetic approaches. First, the receptor elements and cellular factors controlling
TGF-p receptor trafficking as well as the role of retromer in TGF-p stimulated EMT/migration will be defined.
As a number of diseases result from defects in the ability to sort or transport proteins to defined cellular
locales, characterizing the operative trans-acting factors provides potential mechanisms to alter the cellular
response to TGF-p. Second, the role of SNX9 in regulating Smad3-dependent phenotypes including lung
fibrosis and glioblastoma progression will be determined. In that upwards of 45% of all deaths in the
developed wortd are attributed to some sort of chronic fibroproliferative disorder, and the median
progression-free and sun/ival for glioblastoma with current chemoradiation is ~7 and 15 months,
respectively, new approaches are clearly needed.
RELEVANCE (See instructions):
TGF-p is a protein that can be either helpful or harmful to human health. While its ability to stimulate cell
growth is important for normal wound healing, when unchecked the function of many organs can be
disrupted by scar (i.e., fibrosis) formation. Conversely, the growth inhibitory actions of TGF-p are critical in
preventing cancer. The proposed studies will identify/characterize targets that can be used to either increase
or decrease these re.sDnnses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developmental Research Program
-
批准号:10006089
-
项目类别:
-
资助金额:$9.06万
-
财政年份:2018
-
负责人:EDWARD B LEOF
-
依托单位:
TGF BETA RECEPTOR DYNAMICS
-
批准号:2024368
-
项目类别:
-
资助金额:$20.83万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
CAF, A COACTIVATOR OF FOS, AND BREAST CANCER
-
批准号:6124492
-
项目类别:
-
资助金额:$20.45万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF BETA RECEPTOR DYNAMICS
-
批准号:2701838
-
项目类别:
-
资助金额:$21.45万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF Beta Receptor Dynamics
-
批准号:7060521
-
项目类别:
-
资助金额:$30.19万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
Dynamics of Transforming Growth Factor Beta Receptors
-
批准号:6636234
-
项目类别:
-
资助金额:$25.4万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF Beta Receptor Dynamics
-
批准号:8260318
-
项目类别:
-
资助金额:$34.06万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF Beta Receptor Dynamics
-
批准号:8463550
-
项目类别:
-
资助金额:$32.87万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF BETA RECEPTOR DYNAMICS
-
批准号:2910331
-
项目类别:
-
资助金额:$22.08万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF BETA RECEPTOR DYNAMICS
-
批准号:6180737
-
项目类别:
-
资助金额:$22.74万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
Dynamics of Transforming Growth Factor Beta Receptors
-
批准号:6744030
-
项目类别:
-
资助金额:$25.4万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF Beta Receptor Dynamics
-
批准号:7797465
-
项目类别:
-
资助金额:$34.41万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF Beta Receptor Dynamics
-
批准号:9054862
-
项目类别:
-
资助金额:$38.16万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF Beta Receptor Dynamics
-
批准号:7417557
-
项目类别:
-
资助金额:$29.32万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF Beta Receptor Dynamics
-
批准号:6916973
-
项目类别:
-
资助金额:$30.92万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
Dynamics of Transforming Growth Factor Beta Receptors
-
批准号:6519814
-
项目类别:
-
资助金额:$25.4万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF Beta Receptor Dynamics
-
批准号:8842648
-
项目类别:
-
资助金额:$38.16万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF Beta Receptor Dynamics
-
批准号:9262236
-
项目类别:
-
资助金额:$38.16万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
Dynamics of Transforming Growth Factor Beta Receptors
-
批准号:6335939
-
项目类别:
-
资助金额:$25.4万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
TGF Beta Receptor Dynamics
-
批准号:8067077
-
项目类别:
-
资助金额:$34.06万
-
财政年份:1997
-
负责人:EDWARD B LEOF
-
依托单位:
海外基金